Anti B Monoclonal Blood Grouping Reagent (IgM)
Pack Sizes Available
Product Description
Technical Specifications
- Antibody Class and Source: Murine monoclonal IgM; produced in vitro from selected hybridoma cell line (mouse B-lymphocyte + mouse myeloma cell fusion); single clone — identical specificity, avidity, and structure across all production lots
- Specificity and Colour Coding: Specific for B antigen on human red blood cells (ABO blood group system); internationally colour-coded YELLOW per global blood grouping reagent convention; calibrated dropper bottle for consistent drop volume
- Titre and Performance: Minimum titre: 1:256 (tube agglutination test against B antigen-positive red cells); strong direct agglutination on slide within 15-30 seconds with B antigen-positive cells; suitable for slide, tube, and microplate techniques
- Storage and Shelf Life: Store at 2-8°C; do not freeze; protect from light; shelf life 24-36 months from manufacture; return to refrigerator after each use; confirm daily reactivity with known B-positive and O (negative) red cell controls
- Regulatory Status: ISO 13845:2016 CE-IVD marked; CDSCO registered IVD reagent (India); for in vitro diagnostic use only; all blood-contact materials handled as potentially infectious; contains sodium azide as preservative
Frequently asked questions
Anti-B Monoclonal Blood Grouping Reagent is an IVD reagent used for the detection and identification of the B antigen on human red blood cells by direct agglutination. It is used in ABO forward blood grouping of patients and donors. Detecting the B antigen determines whether a patient's blood group is B, AB, or O (no B antigen), which is essential for compatibility decisions before blood transfusion, organ transplant, and maternal-neonatal blood group management. It is always used in conjunction with Anti-A Monoclonal Reagent to complete ABO forward typing.
Anti-B blood grouping reagents are internationally colour-coded YELLOW. This is part of a globally standardised colour coding system for ABO blood grouping reagents designed to prevent misidentification: Anti-A is blue, Anti-B is yellow, Anti-AB is typically not separately coded or uses a combined designation. The colour coding is applied to the dropper bottle cap and label so that laboratory personnel can quickly identify the correct reagent by sight — a critical safety measure in blood banking where misidentification of reagents could lead to a fatal transfusion error. This convention is followed by all major blood grouping reagent manufacturers globally.
Anti-B Monoclonal Blood Grouping Reagent must achieve a minimum titre of 1:256 when tested against B antigen-positive red cells in the tube agglutination method. The Tulip Diagnostics Eryscreen combipack confirms Anti-B titre at a minimum of 1:256. This high titre ensures the reagent has sufficient potency to produce strong, unambiguous agglutination reactions in routine ABO grouping. The high titres achievable with monoclonal antibodies compared to polyclonal antisera are one of the primary reasons monoclonal reagents became the global standard for blood grouping.
Anti-B Monoclonal Reagent is formulated for the slide, tube, and microplate techniques. The microplate technique is the basis for high-throughput semi-automated blood grouping in blood centres processing large donor volumes. For fully automated gel card (column agglutination technology) systems such as Bio-Rad IH-500 or Grifols, the Anti-B reagent is pre-incorporated into the gel card microtubes. Standard Anti-B dropper bottle formats are used primarily in manual and semi-automated settings; gel card or automated systems use platform-specific reagent formats.
Blood group B occurs in approximately 8-11% of European populations, with significantly higher frequencies in South Asian populations (25-35%) and notable variation across African ethnic groups (15-25%). In India, approximately 38% of the population carries the B antigen (blood groups B or AB combined), making Anti-B one of the highest-demand reagents in Indian blood bank supply chains. The global prevalence of the B antigen ensures sustained demand for Anti-B reagents in every blood grouping laboratory worldwide, making it one of the most consistently ordered reagents in the laboratory supply portfolio.
On each day of use, the reactivity of Anti-B Monoclonal Reagent should be confirmed by testing with known positive (group B red cells) and negative (group O red cells) controls. The positive control must produce strong agglutination and the negative control must show no agglutination. If either control fails to react as expected, the reagent batch must be quarantined and investigated before patient samples are reported. The reagent should be inspected visually before use — turbidity, colour change, or visible contamination indicates the reagent should not be used.
Microlisa HIV Ag & Ab 4th Generation ELISA Test Kit
Blood screening exists in a category of laboratory work where the margin for error is not just professionally unacceptable but medically catastrophic. A false negative in HIV screening does not just fail a test. It compromises patient safety, undermines transfusion protocols, and exposes healthcare systems to risks that nobody wants to calculate. Microlisa HIV Ag & Ab 4th Generation ELISA was engineered to close the detection window that makes early HIV infection so difficult to identify reliably. This is an in-vitro qualitative enzyme immunoassay designed for simultaneous detection of antibodies to HIV-1 (including Group O and subtype C prevalent in India), HIV-2, and HIV-1 p24 antigen in human serum or plasma. The test is intended for screening of blood donors, diagnostic testing of individuals at risk for HIV infection, and clinical evaluation of patients with AIDS-related symptoms. It represents the fourth generation of HIV ELISA technology, which detects both antibodies and antigens simultaneously rather than antibodies alone. The clinical advantage of 4th generation testing is the shortened window period. Traditional antibody-only tests miss early seroconversion cases where HIV-1 p24 antigen is present but antibodies have not yet developed to detectable levels. By detecting p24 antigen during the acute infection phase (typically 2 to 4 weeks post-exposure), this assay identifies infections approximately 1 to 2 weeks earlier than 3rd generation antibody-only tests. That earlier detection matters critically in blood donor screening and post-exposure monitoring. The assay is based on sandwich ELISA methodology. Microtiter wells are pre-coated with HIV envelope proteins (gp41, C-terminus of gp120 for HIV-1, and gp36 for HIV-2) and anti-p24 monoclonal antibodies. When specimens are added, any HIV antibodies or p24 antigen present bind to the coated antigens or antibodies. After washing, horseradish peroxidase (HRPO) conjugated antigens and anti-p24 antibodies are added, forming a sandwich complex. The colorimetric reaction develops proportionally to the amount of HIV antibodies or antigen present, read at 450nm absorbance. The kit uses color-coded reagents to monitor procedural steps, reducing protocol errors during multi-step workflows. Breakaway microwell strips allow testing flexibility from single specimens to full 96-well plate runs. Storage stability is maintained at 2-8°C with a shelf life of 24 months unopened. Total assay time including incubation steps is approximately 120 minutes. Sensitivity and specificity meet international standards for 4th generation HIV screening. Clinical evaluations demonstrate 100% sensitivity in detecting seroconversion panels and p24 antigen standards quantified down to 200 pg/ml. Specificity exceeds 99.5% when tested against large sample populations. The test detects all major HIV-1 subtypes including Group O and subtype C, which are epidemiologically significant in the Indian subcontinent. For distributors supplying blood banks, transfusion centers, diagnostic laboratories, and public health screening programs, Microlisa HIV Ag & Ab represents a clinically validated 4th generation screening platform with predictable reorder cycles. Sara Wellness has been exporting in-vitro diagnostic kits and laboratory reagents from India for 15 years.
Advantage PAN Malaria Card Rapid Diagnostic Test Kit
Malaria diagnosis in endemic regions operates under time pressure that microscopy cannot always accommodate. A patient presenting with fever in a rural health center at midnight does not have the luxury of waiting until morning for a trained microscopist to arrive, prepare slides, and spend twenty minutes examining blood films under oil immersion. That delay can mean the difference between timely artemisinin treatment and cerebral malaria developing overnight. Advantage PAN Malaria Card was designed to deliver species-level diagnosis in settings where microscopy is impractical or unavailable. This is a rapid visual immunoassay for qualitative detection of all four human Plasmodium species (P. falciparum, P. vivax, P. malariae, P. ovale) based on pan-specific plasmodium lactate dehydrogenase (pLDH) antigen in whole blood. The test provides results within 20 minutes using a simple fingerstick blood sample, no laboratory equipment required, making it ideal for point-of-care testing in primary health centers, rural clinics, field hospitals, and outbreak response settings. The assay is based on sandwich immunochromatography using monoclonal antibodies specific to pLDH, an enzyme produced by all Plasmodium species during their erythrocytic life cycle. When infected blood is added to the test device and assay buffer is applied, red blood cells lyse and pLDH antigen (if present) binds to gold-conjugated anti-pLDH antibodies. This complex migrates along the nitrocellulose membrane and is captured by immobilized anti-pLDH antibodies at the test line, producing a visible pink-purple band that confirms malaria infection. The see-through device design allows direct visualization of sample migration and result development, which helps identify invalid tests caused by insufficient sample volume or improper application. This transparency reduces the ambiguity that plagues some lateral flow devices where internal workings are hidden. Sensitivity and specificity have been validated through WHO malaria RDT evaluation programs using panels of wild and cultured parasites. The test detects parasitemia levels above 100 parasites per microliter of blood for both P. falciparum and P. vivax, which is clinically relevant for symptomatic infections requiring treatment. Specificity exceeds 99% when tested against cross-reactive conditions including dengue, leptospirosis, typhoid, and other febrile illnesses common in malaria-endemic areas. Shelf life is 24 to 30 months when stored at 4-30°C, which is critical for stockpiling in tropical climates where cold chain infrastructure is unreliable. The extended temperature stability means the test remains functional even when stored at ambient temperatures in resource-limited settings. Each kit contains individually sealed test devices, buffer vials, blood collection pipettes, and instructions for use. The test requires no special training beyond basic clinical skills and can be performed by nurses, paramedics, or trained community health workers. For distributors supplying national malaria control programs, public health departments, NGO field operations, and private diagnostic laboratories, Advantage PAN Malaria Card represents a WHO-evaluated rapid diagnostic platform with predictable consumption tied to malaria case loads. Sara Wellness has been exporting rapid diagnostic test kits and laboratory reagents from India for 15 years.
Human Serum Coombs Antisera (Antihuman Globulin Reagent)
Blood banking operates on a fundamental requirement that most people never think about until something goes wrong. Every unit of blood transfused must be confirmed compatible with the recipient's immune system. Every pregnant woman screened for antibodies that could harm her unborn child. Every suspected case of hemolytic anemia investigated for antibodies attacking the patient's own red blood cells. None of this happens without Coombs antisera making the invisible antibodies visible. Human Serum Coombs Antisera is the reagent that makes antiglobulin testing possible in blood banks and immunohematology laboratories worldwide. This is antihuman globulin (AHG) reagent used in both direct and indirect antiglobulin tests (Coombs tests) to detect antibodies and complement components bound to red blood cell surfaces or present free in serum. The reagent is produced by immunizing animals (typically rabbits) with human immunoglobulins, which induces production of polyclonal antibodies specific for human IgG antibodies and complement factor C3d. When added to washed red blood cells coated with IgG or complement, the antihuman antibodies bind to the human antibodies and form bridges between adjacent sensitized cells, causing visible agglutination. The direct antiglobulin test (DAT) detects antibodies or complement already bound to red blood cell surfaces in vivo. This test is critical for diagnosing autoimmune hemolytic anemia, investigating hemolytic transfusion reactions, and diagnosing hemolytic disease of the fetus and newborn. The indirect antiglobulin test (IAT) detects free antibodies circulating in serum or plasma. This test is essential for pre-transfusion antibody screening, crossmatching blood units for compatibility, and prenatal antibody screening in pregnant women. Polyspecific Coombs antisera (like the green-colored reagent shown) contains antibodies against both IgG and C3d complement, providing broad-spectrum detection. When the polyspecific reagent produces a positive result, monospecific antisera (anti-IgG alone or anti-C3d alone) are used for follow-up testing to characterize whether red cells are coated with IgG antibodies, complement, or both. This differentiation is clinically important because it helps determine the cause and clinical significance of the positive test. The reagent is typically dyed green using patent blue and tartrazine to allow easy visual identification during laboratory workflows where multiple reagents are used simultaneously. Storage at 2-8°C maintains reagent potency until the expiration date printed on the bottle, typically 18 to 24 months from manufacture. The reagent contains sodium azide (0.1% w/v) as a preservative, which inhibits bacterial growth but requires careful handling and disposal. Each dropper bottle delivers approximately 40 microliters per drop, allowing precise volumetric dosing during testing. The reagent must not be diluted and should not be used if turbid, as turbidity indicates bacterial contamination or protein aggregation that will compromise test performance. For distributors supplying blood banks, hospital transfusion services, reference immunohematology laboratories, and donor screening centers, Coombs antisera represents an essential reagent with consumption directly tied to transfusion volume and prenatal screening programs. Sara Wellness has been exporting immunohematology reagents and blood banking supplies from India for 15 years.